Country: Denmark

Currently showing 20 clinical trials. Use pagination links to see more trials.

  • CT-EU-00117630

    Study of a New Antibody for Advanced Solid Tumors

    This here clinical trial is testin’ a new drug called RO7247669. It’s a special kind of antibody that targets two proteins on cancer cells, PD-1 and LAG-3. The goal is to see if this new drug can help fight advanced or metastatic solid tumors like melanoma, lung cancer, and esophageal cancer.

    In the first part of the study, they’ll be givin’ different doses of RO7247669 to patients every 2 or 3 weeks through an IV. They’ll be keepin’ a close eye on any side effects or toxicities that might happen. Once they figure out the highest safe dose, they’ll move on to the next part.

    In that second part, they’ll give that highest safe dose to more patients with them specific cancer types. The main things they’ll be lookin’ at are how well the drug works against the tumors, like whether they shrink or stop growin’ for a while. They’ll also keep watchin’ for any side effects over the course of up to 2 years.

    So in a nutshell, this trial aims to find the best and safest dose of this new dual-targeted antibody drug, and see if it can put up a good fight against advanced solid tumors. If you got one of them cancer types and other treatments ain’t workin’, this here trial might be worth considerin’.

    DenmarkSpainUnited Kingdom
  • Study of a New Drug for Moderate to Severe Rotator Cuff Tendinopathy

    This here clinical trial is aimin’ to see if a new medicine called secukinumab can help folks with moderate to severe rotator cuff tendinopathy, which is a painful condition affectin’ the shoulder. The study will compare secukinumab to a placebo, which is like a fake medicine with no real effects.

    Now, if you join this trial, you’ll be given either secukinumab or the placebo by injection under the skin every week or so for the first few months. The doctors won’t know which one you’re gettin’ until later. You’ll also need to keep takin’ any anti-inflammatory medicines and doin’ physical therapy exercises as you normally would.

    The main thing the researchers are lookin’ at is whether secukinumab can better improve your physical shoulder symptoms like pain, weakness, stiffness, and such compared to the placebo. They’ll be askin’ you to rate your symptoms at different points durin’ the 24-week study.

    It’s important to know that you can’t increase your anti-inflammatory medicine doses or get steroid injections durin’ the study, but you can take other pain meds like acetaminophen if needed. The study involves some medical tests too, like MRI scans and X-rays of your shoulder.

    So in a nutshell, this trial aims to find out if secukinumab works better than a placebo at relievin’ the symptoms of rotator cuff tendinopathy when combined with standard treatments like physical therapy and anti-inflammatory drugs. If you’re interested, you’d be closely monitored and get either the new medicine or a placebo for free as part of the study.

    BulgariaCzechiaDenmarkFrancePortugalSlovakiaUnited Kingdom
  • Study on Secukinumab for Rotator Cuff Tendinopathy

    This here clinical trial is aimin’ to see if a new medicine called secukinumab can help folks with moderate to severe rotator cuff tendinopathy, which is a painful condition affectin’ the shoulder. The study will compare secukinumab to a placebo, which is like a fake medicine with no active ingredients.

    Now, if you join this trial, you’ll be given either secukinumab or the placebo by injection under the skin every week for the first month, and then once a month after that for another couple of months. The doctors will be keepin’ a close eye on your shoulder symptoms like pain, weakness, stiffness, and any mechanical issues you might be havin’.

    The main thing they’ll be lookin’ at is how much your physical shoulder symptoms improve after 16 weeks of treatment with secukinumab compared to the placebo. They’ll be usin’ a special questionnaire called the Western Ontario Rotator Cuff Index to measure them symptoms.

    Now, durin’ the trial, you’ll need to keep takin’ any anti-inflammatory medicines you’re already on, and keep up with your physical therapy exercises too. But you won’t be allowed to get no steroid injections or increase your medicine doses without the doctors’ say-so.

    After the 16 weeks of treatment, there’ll be another 8 weeks where the doctors will check if the effects of the medicine are lastin’. So in total, you’d be in the study for around 6 months if you join up.

    DenmarkGreeceHungaryItalyPolandSpain
  • Study of the drug combination mRNA-4157/V940 and Pembrolizumab in the treatment of melanoma

    The aim of this clinical trial is to test whether a new drug called mRNA-4157/V940 in combination with pembrolizumab can help prevent the recurrence of melanoma in people who have already had it. Currently, mRNA-4157/V940 is what is called “individualized neoantigen therapy,” which means it is a therapy created specifically for each patient based on their cancer cells. Doctors give this drug along with pembrolizumab, a drug that helps the immune system fight cancer cells.

    The main goal of this study is to determine whether taking V940 and pembrolizumab together is more effective in preventing melanoma recurrence than taking pembrolizumab alone. Researchers will closely monitor how long it takes for the cancer to return or spread. The study will last for approximately 74 months.

    BelgiumDenmarkFranceGermanyGreeceItalyPolandPortugalSpainSwedenUnited Kingdom
  • Comparison of zibotentan/dapagliflozin with dapagliflozin alone in the treatment of chronic kidney disease with high proteinuria

    The study aims to understand how to better treat people with chronic kidney disease (CKD) and high proteinuria. This study is in its third phase and involves multiple centers where participants will be closely monitored. The main goal is to compare the effectiveness, safety, and how well participants tolerate a combination treatment of zibotentan/dapagliflozin versus dapagliflozin alone.

    During this study, participants will be randomly assigned to one of two groups. One group will receive the combination of zibotentan and dapagliflozin, while the other group will receive only dapagliflozin. Both treatments aim to slow down the decline in kidney function, which is a major concern for people with CKD and high proteinuria. The key measure of success for this study is the change in eGFR from baseline, which is a test used to check how well the kidneys are working, specifically by measuring the estimated glomerular filtration rate (eGFR). This will be assessed at the 24-month mark of the study.

    This research is crucial because it could lead to better treatment options for those suffering from CKD and high proteinuria, potentially improving their quality of life and health outcomes.

    AustriaBulgariaDenmarkFranceGermanyItalyNetherlandsNorwayPolandSlovakiaSpainSwedenUnited Kingdom
  • Exploring encaleret’s effectiveness for Autosomal Dominant Hypocalcemia type 1

    This clinical study is a research project focused on understanding how well and safely a medication called Encaleret works compared to the usual treatments for a condition known as Autosomal Dominant Hypocalcemia Type 1 (ADH1). ADH1 is a rare genetic condition that can lead to low calcium levels in the blood and is often inherited from parents to their children.

    The study is designed to last about 12 months, with an additional option to continue in a longer-term extension for up to 48 months or more, depending on certain conditions. Initially, participants will go through a screening phase to make sure they meet the study requirements.

    Participants will then enter a period where their usual care treatment is maintained, with adjustments only made for safety reasons. Following this, they will be randomly assigned to either continue with their standard care or start taking encaleret. This part of the study allows both the doctors and participants to know which treatment is being used and to adjust the dosage based on blood calcium levels. After 20 weeks, there’s a period to maintain the dose before possibly moving on to the long-term extension phase, where encaleret will be continued.

    The main goal of the study is to see how many participants can reach and maintain their blood and urinary calcium levels within a target range by using encaleret compared to their standard treatments. This is important for managing the symptoms and health risks associated with ADH1.

    This study might be an opportunity for people with ADH1 to try a new treatment option and contribute to research that could help others with the same condition in the future.

    CzechiaDenmarkFranceItalyNetherlands
  • Study on the effectiveness and safety of BBP-418 for Limb Girdle Muscular Dystrophy 2I patients

    This clinical trial is focused on a new treatment option for individuals diagnosed with Limb Girdle Muscular Dystrophy 2I (LGMD2I). This study is designed to explore the efficacy and safety of a medication called BBP-418 (Ribitol), which is administered as an oral solution. The medication is in the form of granules that are mixed with water to create a drinkable solution.

    The aim is to include participants aged 12 to 60 years old, covering a wide range of individuals affected by LGMD2I. Throughout a 36-month period, the study will closely monitor changes in the muscle function and overall health of the participants to determine the effectiveness and safety of BBP-418 in treating LGMD2I.

    A key aspect being observed is the change from baseline in the North Star Assessment for Limb Girdle Muscular Dystrophy after 36 months of treatment. This will aid in understanding the impact of BBP-418 on muscle function. In addition, the frequency and severity of any treatment-emergent adverse events will be tracked to ensure the medication’s safety over the long term.

    This study is a randomized, placebo-controlled, double-blind study, meaning participants will be randomly assigned to receive either the BBP-418 treatment or a placebo, with neither the participants nor the study staff aware of which group they are in. This approach helps ensure the reliability of the study results.

    DenmarkItalyNetherlandsNorwayUnited Kingdom
  • Study of belzutifan for treating advanced cancers

    This clinical trial aim is to test out a new drug called belzutifan, also known as MK-6482 or WELIREG™. It’s a pill patient can take once a day, and the main goal is to see if it can shrink or get rid of tumors in folks with certain types of cancer.

    The cancers the researchers are looking at are pheochromocytoma and paraganglioma, which are tumors that start in the adrenal glands or nervous system. Pancreatic neuroendocrine tumors, tumors related to von Hippel-Lindau disease, advanced gastrointestinal stromal tumors, and other solid tumors with certain genetic changes that involve a protein called HIF-2α, there will be also tested.

    The big thing the researchers are  keeping an eye on is the objective response rate, which means how many folks see their tumors shrink or disappear completely while taking this drug. The researchers will be watching closely for any side effects too, of course, to make sure this new medicine is safe.

    DenmarkFranceGermanyHungaryItalyNetherlandsSpainSwedenUnited Kingdom
  • Exploring the effects of RO7204239 on Muscular Dystrophy

    The introduction of a clinical trial focused on a new treatment option for individuals with Facioscapulohumeral Muscular Dystrophy (FSHD) marks a significant step forward in medical research. The study aims to evaluate the effectiveness of RO7204239, a humanized monoclonal antibody that targets human latent myostatin, in improving the lives of those affected by FSHD.

    Participants are randomly assigned to receive either the study medication, RO7204239, or a placebo, with neither participants nor the study team aware of which treatment is being administered. The medication is given subcutaneously (under the skin) every 4 weeks.

    A crucial focus of the study is assessing the impact of RO7204239 on the muscle volume of the quadriceps femoris, the front thigh muscles, through magnetic resonance imaging (MRI) after 52 weeks of treatment. The trial also prioritizes participant safety and well-being, with close monitoring for any adverse events throughout its duration, which may extend up to 2.5 years.

    Denmark
  • Continued Parsaclisib treatment for B-cell cancer patients

    This is a phase II clinical trial focused on providing continuation of treatment with a drug called parsaclisib to people diagnosed with B-cell malignancies. The main goal of this study is to expand the treatment regimen established in the previous study. Study participants will receive parsaclisib as a stand-alone therapy (monotherapy) or in combination with other therapeutic agents, which may include itacitinib, ruxolitinib or ibrutinib. The study aims to facilitate participants’ ongoing care and contribute to the broader field of medical research by collecting data on the effectiveness and safety of prolonged use of parsaclisib.

    AustriaBelgiumCzechiaDenmarkFranceHungaryItalyNorwayPolandSpainSwedenUnited Kingdom
  • Testing the effectiveness of new drugs in the treatment of age-related macular degeneration

    The study is investigating a potential breakthrough in treating age-related vision loss, specifically neovascular age-related macular degeneration (nAMD). It introduces a novel therapy, OPT-302, and pairs it with Aflibercept, comparing this combination’s effectiveness against the standard treatment. Participants undergo a series of thorough eye examinations and treatments to monitor the progression of their vision health. The research aims to offer a clearer understanding of how these treatments can better manage and possibly improve vision for individuals dealing with nAMD, contributing valuable knowledge to the field of eye health care.

    AustriaBulgariaCzechiaDenmarkFranceGermanyGreeceHungaryItalyNetherlandsPolandSlovakiaSpainUnited Kingdom
  • Advanced endometrial cancer treatment with acasunlimab and pembrolizumab

    In this trial, scientists are trying out a new treatment for advanced endometrial cancer. This treatment involves using a combination of two drugs, acasunlimab (also referred to as GEN1046) and pembrolizumab, to fight the cancer. The study aims to see how well this treatment works and what side effects might happen. Patients taking part in the trial will be divided into two groups and will be given the trial treatment for up to two years. The total time for which each patient will be monitored is about three years. The treatment’s success will be measured by counting how many patients see their cancer shrink or go away for a period of time. Doctors will be closely watching what happens from the first day of the treatment, tracking how the tumours change and noting down any unusual health happenings that could be related to the trial.

    BelgiumDenmarkSpain
  • Testing the safety and effectiveness of astegolimab for chronic lung disease

    The aim of this study is to see if a drug called astegolimab will be effective and safe in people with a lung disease called chronic obstructive pulmonary disease, or COPD. During this study, patients will be divided into 2 groups. One group of patients will receive the drug, the remaining patients will receive a placebo to compare the results. Both groups will not know what they are getting. The study was particularly interested in people suffering from COPD (chronic obstructive pulmonary disease) who smoked or still smoke and often get sick because of it.

    BelgiumDenmarkFranceGermanyNetherlandsSpainSwedenUnited Kingdom
  • Study on new combination therapy for aggressive lymphoma

    This study is about a less common but severe form of cancer known as Diffuse Large B-Cell Lymphoma (DLBCL). It is testing if a new medication called epcoritamab, given with a mix of other commonly used cancer medicines, can help control the disease better. These other medicines include rituximab, cyclophosphamide, doxorubicin hydrochloride, vincristine, and prednisone, which are often collectively referred to as R-CHOP. The study includes about 900 adults from around the world who have recently been diagnosed with this type of lymphoma. They will be split into two groups. One group will get epcoritamab with R-CHOP and then continue with epcoritamab. The other group will get R-CHOP followed by rituximab. Doctors will carefully watch for changes in the disease and for any side effects. There will be many checks on health, including medical exams, blood tests, questionnaires, and monitoring of any side effects.

    AustriaBelgiumBulgariaCzechiaDenmarkFranceGreeceHungaryItalyNetherlandsPolandPortugalSpainSweden
  • Study of the effectiveness of a new drug in the treatment of heart failure and pulmonary hypertension

    This clinical trial explores the potential benefits of AZD3427 for individuals with heart failure (HF) and pulmonary hypertension (PH) Group 2, a condition characterized by increased blood pressure in the lungs due to heart disease. Around 220 participants will be randomly assigned to receive either AZD3427 or a placebo through subcutaneous injections every two weeks for 24 weeks. The trial aims to assess the impact of AZD3427 on reducing pulmonary vascular resistance (PVR) and improving various heart and lung health indicators. Participants will undergo multiple study visits, with the total duration of the study being approximately 32 to 37 weeks.

    AustriaCzechiaDenmarkGermanyItalyNetherlandsPolandSpainSwedenUnited Kingdom
  • Glofitamab and obinutuzumab: new treatment study for Non-Hodgkin’s lymphoma

    In this study, researchers are trying to learn more about a new drug treatment for B-cell Non-Hodgkin’s Lymphoma – a type of blood cancer. The study is happening in many places and is open for patients who have not had success with their previous treatments. The new drug, called glofitamab, will be given to these patients. The amount of glofitamab will be slowly raised to ensure it’s safe. Another drug, obinutuzumab, will be used with glofitamab. The study will go in 3 steps. For the first two steps, the quantity of glofitamab will be increased slowly. When the safest large dose is found, this medicine will be given to more people in the last step.

    BelgiumDenmarkFinlandFranceItalyPolandSpain
  • Testing a new medicine for diabetes and weight loss

    This study tests NNC0519-0130, a new medicine, possibly help people with type 2 diabetes or high body weight by reducing blood sugar levels and appetite. The trial will check how safe the medicine is and how it affects the body, including blood sugar, fat levels, and weight. Participants, both healthy and with diabetes, will receive the medicine or a placebo through injections or orally. The study aims to find the right doses and understand the medicine’s effects over several weeks.

    DenmarkGermany
  • Understanding biliary tract cancer treatment with rilvegostomig and chemotherapy

    This study focuses on a new treatment for biliary tract cancer using the drug rilvegostomig combined with chemotherapy. It is for patients who have had surgery to remove this cancer. The study will compare the effectiveness of rilvegostomig with a placebo in combination with investigator’s choice of chemotherapy options like capecitabine, gemcitabine/cisplatin, or S-1. The main aim is to see if this new treatment can prevent cancer from coming back. About 750 people will take part in this global study, which is in the final phase of testing.

    BelgiumDenmarkGermanyItalyNorwayPolandSpainUnited Kingdom
  • Study on the efficacy of pirtobrutinib for mantle cell lymphoma

    This clinical trial is designed for patients diagnosed with mantle cell lymphoma (MCL), a type of blood cancer. The primary objective of the study is to assess the efficacy of a new drug called pirtobrutinib in comparison to other similar drugs that have received approval from the U.S. Food and Drug Administration (FDA). Participants may be involved in the study for a duration of two years or more, contingent on their condition not worsening. The trial will categorize patients into two groups: one receiving pirtobrutinib, and the other receiving either ibrutinib, acalabrutinib, or zanubrutinib, which are existing FDA-approved drugs for this condition. Throughout the study, the participants’ health condition, symptoms, and any side effects will be closely monitored. Additionally, the effectiveness of the treatments will be measured by evaluating the eventual survival rates of the patients.

    AustriaBelgiumCzechiaDenmarkFranceGermanyHungaryItalyNetherlandsPolandPortugalSpainUnited Kingdom